Group 2F: Triple Negative Breast Cancer; Predictive Biomarkers



Wednesday, Dec 14
2:00 pm – 3:30 pm Eastern Time (US/New York)



Poster #P1-04-02

Gut microbiome diversity correlates with tumor PD-L1 status in metastatic triple negative breast cancer (mTNBC): correlative analysis of gut microbiome and tumoral biomarkers

Poster #PD5-02:

An organoid model system to study resistance mechanisms, predictive biomarkers, and new strategies to overcome therapeutic resistance in early-stage triple-negative breast cancer

Poster authors Jennifer Rosenbluth, M.D, Ph.D. & Tam Binh Bui will attend this session

Mentor: Barbara Bigelow

Barbara is a licensed psychologist and worked most of her life as a high school psychologist. Barbara has had breast cancer for 20 years, the last 7 as metastatic. A vocal advocate for patient research, she herself was in a clinical trial for immunotherapy that landed her in the hospital for 2 months. Along the way she has also survived lung cancer and melanoma. Today she is the Vice President of Metavivor, committed to raising money to fund metastatic breast cancer research. She also blogs about her experiences using humor to inspire hope for others at The Cancer Chronicles.

You may recognize her from the registration desk at the DC Stampede, the 2018 Elements Campaign with her daughter Bridget for #thisismnc, the Count Me In video for the MBC Project, live streaming from LBBC or walking the runway in New York Fashion Week 2019 (#notjustone)

Twitter: @tbigelow1953

Scientist: Lyndsey Crump, Ph.D.

Lyndsey’s interest in cancer research began when her mom was diagnosed with breast cancer in 2009. She finished her undergraduate degree, then got a Master’s degree from the University of Wisconsin, followed by a PhD from the University of Colorado. Her thesis research was on a novel mechanism of endocrine resistance and metastasis in ER+ breast cancer. She is currently a post-doctoral fellow, still in Colorado, where she studies mechanisms of immune evasion and metastasis in both breast and ovarian cancers. Her overall research goal is to complete highly translational studies to inform better therapeutic approaches in the clinic.